These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10963856)

  • 1. Using Haber's law to define the margin of exposure.
    Doull J; Rozman KK
    Toxicology; 2000 Aug; 149(1):1-2. PubMed ID: 10963856
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of Haber's law in standard setting and risk assessment.
    Gaylor DW
    Toxicology; 2000 Aug; 149(1):17-9. PubMed ID: 10963857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haber's rule: a special case in a family of curves relating concentration and duration of exposure to a fixed level of response for a given endpoint.
    Miller FJ; Schlosser PM; Janszen DB
    Toxicology; 2000 Aug; 149(1):21-34. PubMed ID: 10963858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of Reduced Life Expectancy (RLE) model with Haber's Rule to describe effects of exposure time on toxicity.
    Verma V; Yu QJ; Connell DW
    Environ Pollut; 2015 Sep; 204():26-31. PubMed ID: 25898234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Haber's law apply to human sensory irritation?
    Shusterman D; Matovinovic E; Salmon A
    Inhal Toxicol; 2006 Jun; 18(7):457-71. PubMed ID: 16603477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of time in toxicology or Haber's c x t product.
    Rozman KK
    Toxicology; 2000 Aug; 149(1):35-42. PubMed ID: 10963859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of Haber's rule at different ages using a physiologically based pharmacokinetic (PBPK) model for chloroform in rats.
    Evans MV; Boyes WK; Simmons JE; Litton DK; Easterling MR
    Toxicology; 2002 Jul; 176(1-2):11-23. PubMed ID: 12062926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to human health risk assessment based on the signal-to-noise crossover dose.
    Chiu WA; Guyton KZ; Hogan K; Jinot J
    Environ Health Perspect; 2012 Jul; 120(7):a264; author reply a264-5. PubMed ID: 22760062
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of time as a quantifiable variable of toxicity and the experimental conditions when Haber's c x t product can be observed: implications for therapeutics.
    Rozman KK; Doull J
    J Pharmacol Exp Ther; 2001 Mar; 296(3):663-8. PubMed ID: 11181890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The history of toxicology of the "Haber's Constant"].
    Lohs K
    Z Gesamte Hyg; 1990 Mar; 36(3):130-1. PubMed ID: 2186576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some notes on the history of Haber's law.
    Witschi H
    Toxicol Sci; 1999 Aug; 50(2):164-8. PubMed ID: 10478852
    [No Abstract]   [Full Text] [Related]  

  • 12. Haber's rule duration adjustments should not be used systematically for risk assessment in public health decision-making.
    Belkebir E; Rousselle C; Duboudin C; Bodin L; Bonvallot N
    Toxicol Lett; 2011 Jul; 204(2-3):148-55. PubMed ID: 21565258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical review of time-weighted average as an index of exposure and dose, and of its key elements.
    Atherley G
    Am Ind Hyg Assoc J; 1985 Sep; 46(9):481-7. PubMed ID: 4050687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From more to less than Haber's law.
    Schramm KW; Ghergut I; Behechti A; Rozman KK; Kettrup A
    Environ Toxicol Pharmacol; 2002 Jul; 11(3-4):227-32. PubMed ID: 21782606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Mutagens: Dosimetry, Haber's Rule and Linear Systems.
    Olson WH; Cumming RB
    J Theor Biol; 1981 Aug; 91(3):383-95. PubMed ID: 7311586
    [No Abstract]   [Full Text] [Related]  

  • 16. Paracelsus, Haber and Arndt.
    Rozman KK; Doull J
    Toxicology; 2001 Mar; 160(1-3):191-6. PubMed ID: 11246139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative definition of toxicity: a mathematical description of life and death with dose and time as variables.
    Rozman KK
    Med Hypotheses; 1998 Aug; 51(2):175-8. PubMed ID: 9881827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalation exposure assessments under REACH - Problems encountered using the approach recommended by the ECHA guidance R.15.
    Schendel T
    Regul Toxicol Pharmacol; 2022 Dec; 136():105291. PubMed ID: 36372262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly time-variable exposure to chemicals--toward an assessment strategy.
    Ashauer R; Brown CD
    Integr Environ Assess Manag; 2013 Jul; 9(3):e27-33. PubMed ID: 23564608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.